Orchestra BioMed announces data summary supporting AVIM Therapy

Orchestra BioMed (OBIO) announced a data summary supporting the transformative potential of Atrioventricular Interval Modulation, AVIM, Therapy in the management of hypertensive heart disease will be presented in a keynote talk at the Georgia Innovation Summit in Tbilisi, Georgia on October 10, 2025. The presentation will showcase AVIM Therapy as a novel, device-based therapeutic approach targeting hypertensive heart disease progression and its potential to redefine standards of care. The keynote presentation will provide a comprehensive overview of clinical and mechanistic AVIM Therapy results from pilot and long-term follow-up studies, highlighting the therapy’s consistent favorable clinical impact on blood pressure and cardiac function: Immediate, substantial, and sustained blood pressure reduction; Favorable impact on cardiac hemodynamics after 24 months of treatment; Improvement in echocardiographic measures of diastolic function; Potential to halt hypertensive heart disease progression